Phase IB/II of CPX-351 for Relapse Prevention in AML
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 24
- Registration Number
- NCT04990102
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- AML, Adult
- Interventions
- Drug: APG 2575 ramp up arm
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04964518
- Locations
- 🇺🇸
UCLA Medical cetner Division of Hematology, Los Angeles, California, United States
🇺🇸Novant Health, Winston-Salem, North Carolina, United States
🇺🇸MDACC, Houston, Texas, United States
Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Relapsed or Refractory Hematologic Malignancies
- Interventions
- Drug: Omacetaxine
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 6
- Registration Number
- NCT04926285
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, AcuteMinimal Residual Disease
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04920188
- Locations
- 🇺🇸
North Carolina Cancer Hospital (NCCH), Chapel Hill, North Carolina, United States
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 5
- Registration Number
- NCT04914676
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT04912063
- Locations
- 🇺🇸
University of Alabama at Birmingham - Main /ID# 227071, Birmingham, Alabama, United States
🇺🇸Norton Cancer Institute - St Matthews /ID# 228378, Louisville, Kentucky, United States
🇺🇸Massachusetts General Hospital /ID# 227273, Boston, Massachusetts, United States
Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04908852
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT04905407
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UCLA Medical Center Division of Hematology/Oncology, Los Angeles, California, United States
🇺🇸University of Colorado, Denver, Colorado, United States
A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT04887857
- Locations
- 🇺🇸
Local Institution - 104, Stanford, California, United States
🇺🇸Local Institution - 110, Denver, Colorado, United States
🇺🇸Local Institution - 105, Boston, Massachusetts, United States
Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 20
- Registration Number
- NCT04884984
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China